Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396574 · ClinicalTrials.gov registry record · Phase 3
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
NCT04396574 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 558 participants.
The verdict
NCT04396574, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
Study Summary
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Interventions
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04396574
The ClinicalTrials.gov registry entry for NCT04396574 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lasmiditan is the first listed.
NCT04396574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04396574 about?
NCT04396574 is a clinical study titled "A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine". The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
What is the current status of trial NCT04396574?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2020-06-30. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT04396574?
The interventions under investigation include: Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT04396574?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.